THOUGHTFUL, TARGETED RESEARCH FOR ALZHEIMER’S AND DEMENTIA PATIENTS

We’re creating novel operational approaches to shape a whole new – more rigorous – future for cognition research.

DEDICATED AND COMMITTED TEAM

Our experienced Alzheimer’s and Dementia team will make it clear why our clients come back again and again. Our project managers, physicians, statisticians, supply chain managers, central laboratory techs, and operations experts keep a laser focus on the holistic goal—improved patient health—from start to finish. We engage key opinion leaders and regulatory advisors early and often. And we work hard to make each study an experience we’d be proud to offer our own loved ones if they needed it

NATALIA DROSOPOULOU, PhD

Vice President, Project Management, Psychiatry, Alzheimer’s Disease And Other Dementias

Natalia has worked in clinical research for nearly 20 years, focusing primarily on neurology, psychiatry, pain, and pediatrics. Her experience includes small, intricate Phase I studies as well as large global Phase III programs. As Franchise Area Lead for Neuroscience, she provides operational oversight to neuroscience projects, working with bespoke teams to develop operational strategy and to mitigate risk.

TOM BABIC, MD, PHD

VICE PRESIDENT, SCIENTIFIC SOLUTIONS, NEUROSCIENCE

Tom is a therapeutic leader in neurology medical and scientific affairs, with experience in both industry and academia. Tom is a board-certified neurologist and affiliate professor of clinical neurology. At Worldwide, he is responsible for the scientific and medical leadership of global neurology clinical research initiatives. He is involved with protocol design and development and clinical analysis for randomized controlled clinical trials in populations with early and advanced Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, epilepsy, stroke, migraine, and neurodegenerative disorders. He works to implement up-to-date, evidence-based science across Worldwide’s portfolio of clinical drug research and development projects.

STEPHEN COATES

EXECUTIVE DIRECTOR, PROJECT MANAGEMENT, ALZHEIMER’S DISEASE AND OTHER DEMENTIAS

Stephen nurtures engagement within the CNS team at Worldwide to ensure operational excellence across dementia programs. He began his journey in the industry in 1998. Stephen progressed through the ranks from Clinical Research Associate through study management, building a strong portfolio of therapeutic experience before focusing on Alzheimer’s disease and dementia. Having worked for Roche, GSK, Pfizer, Takeda, Kendle and Covance, Stephen joined Worldwide in 2015.

PAULA PENNEY

EXECUTIVE DIRECTOR, PROJECT MANAGEMENT, ALZHEIMER’S DISEASE AND OTHER DEMENTIAS

Paula’s 20 years in the clinical research industry include both CRO and sponsor experience. Paula has managed and provided operational oversight for multifunctional teams on global and domestic projects across Phase I-IV programs in a wide variety of therapeutic areas, with neuroscience being her passion (including Alzheimer’s disease, schizoaffective disorder, bipolar disease with major depression, MCI, and dementia with Lewy bodies). Prior to her career in the clinical research industry, Paula was a critical care multidisciplinary nursing team lead in a busy Toronto hospital—giving her a keen awareness of the patient experience.

  • expert image
  • expert image
  • expert image
  • expert image

Extra support offers a major advantage in a crowded research indication 

Most drug programs in Alzheimer’s and dementia research could benefit from an extensive array of cognition-focused teams ready to apply their knowledge amassed over the past four decades in the neuroscience field. When you work with Worldwide, that’s what you get—a host of experts engaged with you, from site staff all the way through our senior leadership—ready to make your program a success. 

Neuroscience Experience

  • Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and Dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.

Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a dizzying number of compounds and indications in every phase. Now Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services in addition to our top-notch global network of study execution experts.

Learn More

Worldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.

Learn More

Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.

Learn More

A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.

Learn More

Our Team of Neuroscience Functional Experts